文献速递眼底病与葡萄膜炎

COVID-19疫苗接种后疫苗相关葡萄膜炎:疫苗不良事件报告系统数据库分析

Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis.
PubMed 文献 · Ophthalmology · 2022-08-31

该回顾性研究基于美国CDC疫苗不良事件报告系统,分析2020年12月11日至2022年5月9日全球40个国家1094例接种BNT162b2、mRNA-1273和Ad26.COV2.S后报告的疫苗相关葡萄膜炎(VAU)。粗报告率低(每百万剂0.57、0.44、0.35),观察值与预期值比值相近(0.023、0.025、0.027),提示VAU安全性担忧较低;mRNA-1273组发病间隔显著长于BNT162b2组和rAd26.COV2.S组(P<0.0001)。

要点

  • 全球40国报告1094例VAU,BNT162b2占77.97%(n=853)。
  • 粗报告率每百万剂:BNT162b2 0.57、mRNA-1273 0.44、Ad26.COV2.S 0.35。
  • mRNA-1273组发病间隔21.22±42.74天,显著长于BNT162b2组11.42±23.16天和rAd26.COV2.S组12.69±16.02天(P<0.0001)。

核心结论

  • 低粗报告率和观察值与预期值比值提示VAU安全性担忧较低。
  • 研究提示报告VAU事件与SARS-CoV-2疫苗之间可能存在时间关联,但需进一步研究阐明相关免疫机制。

研究设计与样本

  • 回顾性研究,数据来自美国CDC疫苗不良事件报告系统,时间范围为2020年12月11日至2022年5月9日。
  • 纳入全球接种BNT162b2、mRNA-1273和Ad26.COV2.S疫苗后诊断为VAU的患者。
  • 对人口学、临床病史和表现进行描述性分析,评估3种疫苗与连续变量和分类变量的相关性,并进行事后分析和接种后30天VAU发病风险分析。

主要发现

  • 共报告1094例VAU,来自40个国家;BNT162b2组853例(77.97%)。
  • 患者平均年龄46.24±16.93岁,女性占68.65%(n=751)。
  • 多数病例报告于第一剂接种后(n=452,41.32%)和接种后第一周内(n=591,54.02%)。
  • VAU发病间隔:mRNA-1273组21.22±42.74天,显著长于BNT162b2组11.42±23.16天和rAd26.COV2.S组12.69±16.02天(P<0.0001)。
  • 事后分析显示BNT162b2组发病间隔显著短于mRNA-1273组(P<0.0001);30天风险分析显示3种疫苗间差异显著(P<0.0001)。

关键数值与推荐

  • 估计全球粗报告率(每百万剂):BNT162b2 0.57、mRNA-1273 0.44、Ad26.COV2.S 0.35。
  • 美国观察值与预期值比值:BNT162b2 0.023、mRNA-1273 0.025、Ad26.COV2.S 0.027。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the risk of vaccine-associated uveitis (VAU) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and evaluate uveitis onset interval and clinical presentations in the patients. DESIGN: A retrospective study from December 11, 2020, to May 9, 2022, using the Centers for Disease Control and Prevention Vaccine Adverse Event Reporting System. PARTICIPANTS: Patients diagnosed with VAU after administration of BNT162b2 (Pfizer-BioNTech, Pfizer Inc/BioNTech SE), mRNA-1273 (Moderna, Moderna Therapeutics Inc), and Ad26.COV2.S (Janssen, Janssen Pharmaceuticals) vaccine worldwide. METHODS: A descriptive analysis of the demographics, clinical history, and presentation was performed. We evaluated the correlation among the 3 vaccines and continuous and categorical variables. A post hoc analysis was performed between uveitis onset interval after vaccination and age, dose, and vaccine type. Finally, a 30-day risk analysis for VAU onset postvaccination was performed. MAIN OUTCOME MEASURES: The estimated global crude reporting rate, observed to expected ratio of VAU in the United States, associated ocular and systemic presentations, and onset duration. RESULTS: A total of 1094 cases of VAU were reported from 40 countries with an estimated crude reporting rate (per million doses) of 0.57, 0.44, and 0.35 for BNT162b2, mRNA-1273, and Ad26.COV2.S, respectively. The observed to expected ratio of VAU was comparable for BNT162b2 (0.023), mRNA-1273 (0.025), and Ad26.COV2.S (0.027). Most cases of VAU were reported in patients who received BNT162b2 (n = 853, 77.97%). The mean age of patients with VAU was 46.24 ± 16.93 years, and 68.65% (n = 751) were women. Most cases were reported after the first dose (n = 452, 41.32%) and within the first week (n = 591, 54.02%) of the vaccination. The onset interval for VAU was significantly longer in patients who received mRNA-1273 (21.22 ± 42.74 days) compared with BNT162b2 (11.42 ± 23.16 days) and rAd26.COV2.S (12.69 ± 16.02 days) vaccines (P < 0.0001). The post hoc analysis revealed a significantly shorter interval of onset for the BNT162b2 compared with the mRNA 1273 vaccine (P < 0.0001). The 30-day risk analysis showed a significant difference among the 3 vaccines (P < 0.0001). CONCLUSIONS: The low crude reporting rate and observed to expected ratio suggest a low safety concern for VAU. This study provides insights into a possible temporal association between reported VAU events and SARS-CoV-2 vaccines; however, further investigations are required to delineate the associated immunological mechanisms.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Singh RB, Parmar UPS, Kahale F, et al. Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis. Ophthalmology. 2022. PMID: 36055601. doi:10.1016/j.ophtha.2022.08.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。